

Continuing Education/Continuing Medical Education (CE/CME)

MOUD in Primary Care: Medication for Opioid Use Disorder in an **Office-based Setting**

WHEN: December 15, 2022 — 2-3 PM CT/ 3-4 PM ET

Join the Webinar:

Google Meet joining info

Video call link: https://meet.google.com/ffe-acnf-aqa Or dial: ?(US) +1 757-744-3457? PIN: ?920 936 468?#

Presentation purpose:

This program is intended for the primary care provider and other applicable clinicians to increase knowledge around the process for initiating medications for opioid use disorder (MOUD), including the process for X-waiver, pharmacotherapy for MOUD and practice process for implementing this care.



Funding for this initiative was made possible (in part) by grant no. 1H79TI)83343 from SAMHSA. The views expressed in written conference materials or publications and speakers

and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Learning objectives:

- The Opioid Epidemic: overview, current status, and terminology
- Review the importance of MOUD in reducing opioid overdoses and engaging in recovery pathways
- Describe the process of obtaining the 'X' Waiver for buprenorphine prescribing
- Review common clinic workflow for providing buprenorphine in a primary care office
- Review resources for ongoing education and support

Target audience:

This activity is designed for the interdisciplinary audience including the following: Physician, Physician Assistant, Pharmacist, Nurse, Pharmacy Technician, Advanced Practice Nurse

Commercial Support:

No commercial interest was received for this CE/CME activity.

Accreditation:



In support of improving patient care, Ascension is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit designation:

This activity was planned by and for the healthcare team, and learners will receive 1.00 IPCE credit(s) for learning and change.



Ascension designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



This activity is awarded 1.00 ANCC contact hour(s). (based on 60 minutes per contact hour)



Ascension has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PAs should

only claim credit commensurate with the extent of their participation.



This knowledge-based activity qualifies for 1.00 contact hours of continuing pharmacy education credit. Pharmacy CE credits will be submitted electronically to the NABP upon successful completion of the

Faculty/Course Director/Planners:

Ascension has selected all faculty participating in this activity. It is the policy of Ascension that all CE/CME planning committees, faculty, authors, editors, and staff disclose relationships with commercial interests upon nomination or invitation of participation. Disclosure documents are reviewed for potential conflicts of interest and if relevant, they are resolved prior to confirmation of participation. Only those participants who have no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this activity.

Conflict of Interest:

In accordance with the ACCME Standards for Commercial Support, it is the policy of Ascension to ensure balance, independence, objectivity and scientific rigor in all CE/CME activities. Full disclosure of conflicts and conflict resolution will be made in writing via handout materials or syllabus.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Kati Shell, PharmD	Activity Coordinator	Nothing to disclose - 05/02/2022
Samuel Parish, MD, FASAM	Faculty	Nothing to disclose - 11/14/2022